Merck and Novartis chiefs outline what's on the M&A menu in 2017
Every quarter Big Pharma CEOs almost inevitably get to answer at least one question from a prominent analyst about their next acquisition. This year, the questions have become more pointed as more of the Big 10 players talk a good game, but rarely seem to deliver—unless their name is Pfizer.
Here’s the bottom line on what we found out on Tuesday: Bolt-ons are still all the rage in M&A.
Merck, which has been a very cautious player since its Cubist buyout, wants anything new on the deal table to be easily clipped into the company’s current structure. Sound familiar?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.